Does Argos Therapeutics, Inc. (ARGS) Have Any Gas After Achieving 52-Week Low?

January 22, 2018 - By Vivian Park

Investors sentiment increased to 0.63 in Q3 2017. Its up 0.09, from 0.54 in 2017Q2. It increased, as 13 investors sold Argos Therapeutics, Inc. shares while 6 reduced holdings. 8 funds opened positions while 4 raised stakes. 2.64 million shares or 38.27% more from 1.91 million shares in 2017Q2 were reported.
Comml Bank Of Ny Mellon holds 0% or 74,379 shares in its portfolio. Barclays Public Limited holds 0% or 100 shares in its portfolio. Hightower Ltd, Illinois-based fund reported 32,071 shares. Deutsche Bancshares Ag reported 36 shares or 0% of all its holdings. California Employees Retirement owns 0% invested in Argos Therapeutics, Inc. (NASDAQ:ARGS) for 94,800 shares. Ohio-based Meeder Asset Management has invested 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Blackrock accumulated 7,054 shares or 0% of the stock. Utah-based Wasatch Advisors has invested 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Millennium Ltd Liability holds 180,032 shares. Stifel holds 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS) or 65,550 shares. Keybank Association Oh reported 119,515 shares. Royal Retail Bank Of Canada reported 1,651 shares. Bnp Paribas Arbitrage Sa reported 4 shares. State Street Corp holds 11,900 shares. Two Sigma Secs Ltd Limited Liability Company holds 0% or 149,999 shares.

The stock of Argos Therapeutics, Inc. (NASDAQ:ARGS) hit a new 52-week low and has $2.04 target or 7.00 % below today’s $2.19 share price. The 5 months bearish chart indicates high risk for the $12.38 million company. The 1-year low was reported on Jan, 22 by If the $2.04 price target is reached, the company will be worth $866,390 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock increased 1.39% or $0.0301 during the last trading session, reaching $2.1901. About 454,240 shares traded or 78.86% up from the average. Argos Therapeutics, Inc. (NASDAQ:ARGS) has declined 92.57% since January 22, 2017 and is downtrending. It has underperformed by 109.27% the S&P500.

Argos Therapeutics, Inc. (NASDAQ:ARGS) Ratings Coverage

Among 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Argos Therapeutics had 6 analyst reports since November 16, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, August 11 by FBR Capital. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The rating was maintained by FBR Capital with “Outperform” on Monday, November 16. Roth Capital maintained the stock with “Buy” rating in Tuesday, April 19 report. As per Tuesday, November 17, the company rating was maintained by Needham. The company was maintained on Thursday, September 21 by Needham.

More news for Argos Therapeutics, Inc. (NASDAQ:ARGS) were recently published by:, which released: “Argos Therapeutics Inc. (NASDAQ: ARGS) technicals should not be ignored” on January 22, 2018.‘s article titled: “Argos Therapeutics (ARGS) Planes 1-for-20 Reverse Stock Split” and published on January 18, 2018 is yet another important article.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $12.38 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.